Patents by Inventor Frank Kolbinger
Frank Kolbinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357381Abstract: Described herein are multispecific antibodies targeting IL-13 and IL-18. The multispecific antibodies can be antagonistic and/or therapeutic antibodies targeting IL-13 and IL-18. Also described herein are methods of making said multispecific antibodies, methods of inhibiting IL-13 and IL-18 simultaneously with said multispecific antibodies, and methods of treating an IL-13/IL-18 mediated disorder, such as atopic dermatitis, by administering a multispecific antibody described herein.Type: ApplicationFiled: April 25, 2023Publication date: November 9, 2023Inventors: Michael Otto BARDROFF, Regis CEBE, Jiri KOVARIK, Frank KOLBINGER, Michael KIFFE, Anett RITTER, Lukas ROTH
-
Publication number: 20230331834Abstract: The present disclosure relates to methods for treating tendinopathy, e.g., rotator cuff tendinopathy, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists. e.g., IL-17 antibodies, such as secukinumab, for treating tendinopathy patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.Type: ApplicationFiled: January 9, 2023Publication date: October 19, 2023Inventors: Gerard Bruin, Shea Carter, Frank Kolbinger, Iain McInnes, Neal Millar, Linda Mindeholm, Matthias Schieker, Eckhard Weber
-
Publication number: 20210179702Abstract: The present disclosure relates to methods for treating tendinopathy, e.g., rotator cuff tendinopathy, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating tendinopathy patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.Type: ApplicationFiled: November 1, 2018Publication date: June 17, 2021Inventors: Gerard Bruin, Shea Carter, Frank Kolbinger, Iain McInnes, Neal Millar, Linda Mindeholm, Matthias Schieker, Eckhard Weber
-
Publication number: 20140193408Abstract: The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having VH, CH1, CH2, and CH3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the VH region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a VL and CL region; and (d) a monovalent region of a mammalian binding molecule fused to the VL region; characterised in that each pair of VH and VL CDR sequences has specificity for an antigen, such that the total valency of said soluble protein is six.Type: ApplicationFiled: June 15, 2012Publication date: July 10, 2014Applicant: NOVARTIS AGInventors: Thomas Huber, Frank Kolbinger, Karl Welzenbach
-
Publication number: 20130011401Abstract: The present invention relates to soluble SIRP? binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRP? binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first monovalent single chain polypeptide comprising a first SIRP? binding domain fused at the N-terminal part of a heavy chain constant region of an antibody; and, (ii) a second monovalent single chain polypeptide comprising a second SIR % binding domain fused at the N-terminal part of a CL light chain constant region of an antibody. The invention further relates to soluble SIRP-binding antibody-like protein as shown in FIG. 1.Type: ApplicationFiled: December 21, 2010Publication date: January 10, 2013Applicant: NOVARTIS AGInventors: Thomas Huber, Frank Kolbinger, Marie Sarfati, Karl Welzenbach
-
Publication number: 20110076270Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.Type: ApplicationFiled: June 30, 2010Publication date: March 31, 2011Inventors: Gregorio AVERSA, Frank KOLBINGER, José M. CARBALLIDO HERRERA, Andreás ASZÓDI, José W. SALDANHA, Bruce M. HALL
-
Publication number: 20100322930Abstract: The invention provides fibronectin-based binding molecules and methods for introducing donor CDRs into a fibronectin-based binding scaffold, in particular, Fn3. The fibronectin-based binding molecules of the invention may be further conjugated to another moiety, for example, Fc, anti-FcRn, HSA, anti-HSA, and PEG, for improved half life and stability, particularly in mammalian cells. The invention also provides methods for screening such molecules for binding to a target antigen as well as the manufacture and purification of a candidate binder.Type: ApplicationFiled: December 22, 2008Publication date: December 23, 2010Inventors: Frank Kolbinger, Karen Jane Vincent, Barbara Brannetti, Stefan Ewert
-
Patent number: 7825222Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.Type: GrantFiled: December 8, 2005Date of Patent: November 2, 2010Assignee: Novartis AGInventors: Gregorio Aversa, Frank Kolbinger, Josè M Carballido Herrera, András Aszódi, José W Saldanha, Bruce M Hall
-
Publication number: 20070275391Abstract: The present invention relates to in particular immune modulatory polypeptides and polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of diseases whereby immune responses initiated by dendritic cells (DC), monocytes or lymphocytes, play a causal or contributory role.Type: ApplicationFiled: September 29, 2006Publication date: November 29, 2007Inventors: Gung-Wei Chirn, Uwe Dengler, Frank Kolbinger, Quicheng Ma, Nanguneri Nirmala, Klaus Seuwen, Gudrun Werner
-
Publication number: 20060088525Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.Type: ApplicationFiled: December 8, 2005Publication date: April 27, 2006Inventors: Gregorio Aversa, Frank Kolbinger, Jose Carballido Herrera, Andras Aszodi, Jose Saldanha, Bruce Hall
-
Publication number: 20050107589Abstract: The present invention relates to in particular immune modulatory polypeptides and polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of diseases whereby immune responses initiated by dendritic cells (DC), monocytes or lymphocytes, play a causal or contributory role.Type: ApplicationFiled: December 16, 2002Publication date: May 19, 2005Inventors: Gung-Wei Chirn, Uwe Dengler, Frank Kolbinger, Qicheng Ma, Nanguneri Nirmala, Klaus Seuwen, Gudrun Werner
-
Publication number: 20050069538Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gin (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.Type: ApplicationFiled: September 18, 2003Publication date: March 31, 2005Inventors: Gregorio Aversa, Frank Kolbinger, Jose Carballido Herrera, Andras Aszodi, Jose Saldanha, Bruce Hall
-
Publication number: 20040096901Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYTH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFYNHGTKYNEKFKG) and said CDR3 having the amino acid seuqnce Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln 8RASQNIGTSIQ), CDR′, having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chmieric or humanised antibody, useful as a pharmaceutical.Type: ApplicationFiled: January 5, 2004Publication date: May 20, 2004Inventors: Gregorio Aversa, Frank Kolbinger, Jos?eacute; M Carballido Herrera, Andr?aacute;s Aszdi, Jos?eacute; W Saldanha, Bruce M Hall
-
Patent number: 6072035Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.Type: GrantFiled: June 7, 1995Date of Patent: June 6, 2000Assignees: Novartis Corporation, Tanox Biosystems, Inc.Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha
-
Patent number: 6066718Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.Type: GrantFiled: September 27, 1993Date of Patent: May 23, 2000Assignees: Novartis Corporation, Tanox Biosystems, Inc.Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha
-
Patent number: 5958708Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.Type: GrantFiled: June 7, 1995Date of Patent: September 28, 1999Assignees: Novartis Corporation, Tanox Biosystems, Inc.Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha